15 November 2022

Successful participation of VIVEbiotech in international events in 2022

VIVEbiotech has successfully participated in 7 international events during 2023.

Read more

11 November 2022

VIVEbiotech presents its highly flexible and customized approach to lentiviral vector manufacturing at BioProcess International

VIVEbiotech has presented a webinar entitled “Flexible and Customized Approach to Lentiviral Vector Development and Manufacture Through a Well-Established Platform” last Tuesday, November 8.

Read more

24 October 2022

VIVEbiotech participates in the 4th edition of New Culturers Gunea

VIVEbiotech has participated in the 4th edition of New Culturers Gunea that took place in FabrikaNCE last 19th October: a very interesting event to show...

Read more

21 October 2022

Gurutz Linazasoro, CEO of VIVEbiotech, participates in a conference organized by AseBio and CIBER

Gurutz Linazasoro, CEO of VIVEbiotech, has participated in the conference called "Terapias avanzadas (TA): de la academia a la industria" organized by AseBio, the Spanish...

Read more

19 October 2022

VIVEbiotech presents its highly optimized transfection process in a webinar with Polyplus

VIVEbiotech has participated in a webinar entitled “The importance of raw materials to succeed in lentiviral vector manufacturing” together with Polyplus.

Read more

13 October 2022

VIVEbiotech´s scalable, regulatory compliant and cost-effective platform presentation together with Univercells Technologies

VIVEbiotech has participated in a webinar entitled “How to find success with lentiviral production using fixed bed bioreactor technology?” together with Univercells Technologies.

Read more

21 September 2022

VIVEbiotech, one of the three only companies to obtain a PERTE

VIVEbiotech has obtained the PERTE called “Salud de Vanguardia/State-Of-The-Art Health” by the Ministry of Industry of the Spanish Government which is financed with European...

Read more

21 June 2022

VIVEbiotech continues the expansion of its lentiviral vector manufacturing capabilities to address the viral vector bottleneck

VIVEbiotech, a gene transfer technologies Contract Development and Manufacturing Organization (CDMO) developing and GMP manufacturing lentiviral vectors, today announces its Good Manufacturing Practice (GMP)-accredited...

Read more

4 May 2022

Interview with Natalia Elizalde in The Medicine Maker

The Business Development Director of VIVEbiotech Dr. Natalia Elizalde was interviewed by The Medicine Maker on the challenges of lentiviral vector manufacture/use.

Read more

2 May 2022

Gurutz Linazaroso, the CEO of VIVEbiotech, in the Medicine Maker Power List 2022

The CEO of VIVEbiotech, Dr. Gurutz Linazasoro, is part of the prestigious The Medicine Maker Power List

Read more